Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1

Cancer Research

Volumn 60, Issue 9, 2000, Pages 2435-2443

  Carr Brendel, Victoria ^a   Markovic, Dubravka ^a   Ferrer, Karen ^a   Smith, Michael ^b   Taylor Papadimitriou, Joyce ^b   Cohen, Edward P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL MEDIATED CYTOTOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ADENOCARCINOMA; ANIMALS; BLOTTING, SOUTHERN; CA-15-3 ANTIGEN; CYTOKINES; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-2; INTERLEUKIN-4; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, TRANSGENIC; MUCINS; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0034193383     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Fearon, E. R., Pardoll, D. M, Itaya, T., Golumbek, P. T., and Levitsky, H. I. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60: 397-403, 1990.
2. Cavallo, F., Pierro, F. D., Giovarelli, M., Gulino, A., Vacca, A., Stoppacciario, A., Forni, M., Modesti, A., and Forni, G. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res., 53: 5067-5070, 1993.
3. Connor, J., Bannerji, R., Saito, S., Heston, W., Fair, W., and Gilboa, E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J. Exp. Med., 177: 1127-1134, 1993.
4. Chakravarty, P. K., Fuji, H., Abu-hadid, M. M., Hsu, S-C, and Sood, A. K. Tumorigenicity of interleukin-2 (IL-2)-cDNA-transfected L1210 lymphoma and its in vivo variants is modulated by changes in IL-2 expression: potential therapeutic implications. Cancer Immunol. Immunother., 35: 347-354, 1992.
5. Russell, S. J., Eccles, S. A., Flemming, C. L., Johnson, C. A., and Collins, M. K. L. Decreased tumorigenicity of a transplantable sarcoma following transfer and expression of IL-2 cDNA. Int. J. Cancer, 47: 244-251, 1991.
6. Hock, H., Dorsch, M., Kunzendorf, U., Qin, Z., Diamanstein, T., and Blankenstein, T. Mechanism of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon γ. Proc. Natl. Acad. Sci. USA, 90: 2774-2778, 1993.
7. Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., and Pardoll, D. M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (Washington DC), 254: 713-716, 1991.
8. Columbo, M. P., Ferrari, G., Stoppacciaro, A., Parenza, M., Rodolfo, M., Mavilio, F., and Parmiani, G. Granulocyle colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med., 173: 889-897, 1991.
9. Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
10. Gansbacher, B., Bannerji, R., Daniels, B., Zier, K., Cronin, K., and Gilboa, E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res., 50: 7820-7825, 1990.
11. Nayak, S. K., McCallister, T., Han, L. J., Gangavalli, R., Barber, J., and Dillman, R. O. Transduction of human renal carcinoma cells with human γ-interferon gene via retroviral vector. Cancer Gene Ther., 3: 143-150, 1996.
12. Zitvogel, L., Tahara, H., Robbins, P. D., Storkus, W. J., Clarke, M. R., Nalesnik, M. A., and Lotze, M. T. Cancer immunotherapy of established tumors with IL-12. J. Immunol., 155: 1393-1403, 1995.
13. Tahara, H., Zeh, H. J., Storkus, W. J., Pappo, I., Watkins, S. C., Gubler, U., Wolf, S. F., Robbins, P. D., and Lotze, M. T. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res., 54: 182-189, 1994.
14. Pardoll, D. M. Paracrine cytokine adjuvants in cancer therapy. Annu. Rev. Immunol., 13: 399-415, 1995.
15. Miles, D. W., and Taylor-Papadimitriou, J. Mucin-based breast cancer vaccines. Expert Opin. Invest. Drugs, 7: 1865-1871, 1998.
16. Reddish, M. A., MacLean, G. D., Koganty, R. R., Kan-Mitchell, J., Jones, V., Mitchell, M. S., and Longenecker, B. M. Anti-MUC1 class 1 restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide. Int. J. Cancer, 76: 817-825, 1998.
17. Taylor-Papadimitriou, J., Stewart, L., Burchell, J., and Beverly, P. The polymorphic epithelial mucin as a target for immunotherapy. Ann. NY Acad. Sci., 690: 69-79, 1990.
18. Kotera, Y., Fontenot, J., Pecher, G., Metzgar, R., and Finn, O. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res., 54: 2856-2863, 1994.
19. Barnd, D. L., Lan, M. S., Metzgar, R. S., and Finn, O. J. Specific major histocompatibility complex-unrestricted recognition of tumor associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA, 86: 7159-7166, 1989.
20. Finn, O. J., Jerome, K. R., Henderson, R. A., Pecher, G., Domenech, N., Magarian-Blander, J., and Barratt-Boyes, S. M. MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol. Rev., 154: 61-90, 1995.
21. Domenech, N., Henderson, R. A., and Finn, O. J. Identification of an HLA-11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol., 155: 4766-4773, 1995.
22. Burchell, J., and Taylor-Papadimitriou, J. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core protein epitopes of the MUC1 gene product. Epithelial Cell Biol., 2: 155-161, 1993.
23. Lloyd, K. O., Burchell, J., Kudryashov, V., Yin, B. W. T., and Taylor-Papadimitriou, J. Comparison of O-linked carbohydrate chains in MUC1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. J. Biol. Chem., 271: 33325-33331, 1996.
24. Zotter, S., Hageman, P. C., Lossnitzer, A., Mooi, W. J., and Hilgers, J. Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev., 11-12: 55-101, 1988.
25. Peat, N., Gendler, S. J., Lalani, N., Duhig, T., and Taylor-Papadimitriou, J. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res., 52: 1954-1960, 1992.
26. Miller, F. R., Miller, B. E., and Heppner, G. H. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis, 3: 22-31, 1983.
27. Lalani, E. N., Berdichevsky, F., Boshell, M., Shearer, M., Wilson, D., Stauss, H., Gendler, S. J., and Taylor-Papadimitriou, J. Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity. J. Biol. Chem., 266: 15420-15427, 1991.
28. Blochlinger, K., and Diggelmann, H. Hygromycin B phosphotransferase as a selectable marker for DNA transfer experiments with higher eucaryotic cells. Mol. Cell. Biol., 4: 2929-2931, 1984.
29. Tahara, M., and Lotze, M. T. Anti-tumor effects of IL-12. Applications for the immunotherapy and gene therapy of cancer. Gene Ther., 2: 96-106, 1995.
30. Girling, A., Barkova, J., Burchell, J., Gendler, S., Gillet, C., and Taylor-Papadimitriou, J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer, 43: 1072-1076, 1989.
31. Burchell, J., Taylor-Papadimitriou, J., Boshell, M., Gendler, S., and Duhig, T. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int. J. Cancer, 44: 691-696, 1989.
32. Jerome, K. R., Barnd, D. L., Bendt, K. M., Boyer, C. M., Taylor-Papadimitriou, J., McKenzie, I. F., Bast, R. C., Jr., and Finn, O. J. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res., 57: 2908-2916, 1991.
33. Cohen, E. P., and Kim, T. S. Neoplastic cells that express low levels of MHC class I determinants escape host immunity. Semin. Cancer Biol., 5: 419-428, 1994.
34. Puisieux, I., Odin, L., Poujol, D., Moingeon, P., Tartaglia, J., Cox, W., and Favrst, M. Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term anti tumor immunity. Hum. Gene Ther., 9: 2481-2492, 1998.
35. Cho, B. K,. Wang, C., Sugawa, S., Eisen, H., and Chen, J. Functional differences between memory and naive CD8 T cells. Proc. Natl. Acad. Sci. USA, 96: 2976-2981, 1999.
36. Price, D. A., Klenerman, P., Booth, B., Phillips, R. E., and Sewall, A. Cytotoxic T lymphocytes, chemokines and anti viral immunity. Immunol. Today, 20: 212-216, 1999.
37. Pattron, S., Gendler, S. J., and Spicer, A. P. The epithelial mucin, MUC-1, of milk, mammary gland and other tissues. Biochim. Biophys. Acta, 1241: 407-424, 1995.
38. Kennedy, M. K., Picha, K. S., Shanebeck, K. D., Anderson, D. M., and Grabstein, K. H. IL-12 regulates the proliferation of Th1, but not Th2 or Th0 clones. Eur. J. Immunol., 24: 2271-2277, 1994.
39. Gemann, T., and Rude, E. Interleukin-12. Int. Arch. Allergy Immunol., 108: 103-112, 1995.
40. Zitvogel, L., Tahara, H., Robbins, P. D., Storkus, W. J., Clarke, M. R., Nalesnik, M. A., and Lotze, M. T. Cancer immunotherapy of established tumors with IL-12. J. Immunol., 155: 1393-1403, 1995.
41. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M. Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993.
42. Hendrzak, J. A., and Brunda, M. J. Antitumor and antimetastatic activity of IL-12. Curr. Top. Microbiol. Immunol., 213 (Part 3): 65-83, 1996.
43. Gendler, S. J., and Spicer, A. P. Epithelial mucin genes. Annu. Rev. Physiol., 57: 607-634, 1995.
44. Disis, M. L., Calenoff, E., McLaughlin, G., Murphy, E., Chen, W., Groner, B., Jeschke, M., Lydon, N., McGlynn, E., and Livingston, R. B. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res., 54: 16-20, 1994.
45. Peoples, G. E., Goedegeburre, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J. Breast and ovarian cancer-specific cylotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
46. Schlichtholz, B., Legros, Y., Gillet, D., Gaillard, C., Marty, M., Lane, D., Calvo, F., and Soussi, T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hotspot. Cancer Res., 52: 6380-6384, 1992.
47. Toso, J. F., Oei, C., Oshidari, F., Tartaglia, J., Paoletti, E., Lyerly, H. K., Talib, S., and Weinhold, K. J. MAGE-1-specific precursor cytotoxic T lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. Cancer Res., 56: 16-20, 1996.
48. Fuije, T., Mori, M., Ueo, H., Sugimachi, K., and Akioshi, T. Expression of MAGE and BAGE genes in Japanese breast cancers. Ann. Oncol., 8: 369-372, 1997.
49. Risinger, J. I., Berchuck, A., Kohler, M. F., Watson, P., Lynch, H. T., and Boyd, J, Genetic instability of microsatellites in endometrial carcinoma. Cancer Res., 53: 5100-5103, 1993.
50. Waltz, M. R., Pandelitis, S. M., Pratt, W., Barnes, D., Swallow, D. M., Gendler, S., and Cohen, E. P. A microsatellite within the MUC1 locus at 1q21 is altered in the neoplastic cells of breast cancer patients. Cancer Genet. Cytogenet., 100: 63-67, 1998.
51. Peltomaki, P., Lothe, R., Aaltonen, L. A., Pylkkanen, L., Nystrom-Lanti, M., Servca, R., David, L., Holm, R., Ryberg, D., and Haugen, A. Microsatellite instability is associated with tumors that characterize the HNPCC syndrome. Cancer Res., 53: 5853-5855, 1993.